A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Start Date:March 2011
End Date:June 2016
Contact:Reference Study ID Number: DST4964g www.roche.com/about_roche/roche_worldwide.htm
Email:global.rochegenentechtrials@roche.com
Phone:888-662-6728 (U.S. Only)

Use our guide to learn which trials are right for you!

A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered
as a single agent by intravenous (IV) infusion to patients with metastatic
Castration-Resistant Prostate Cancer (CRPC).


Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Life expectancy of at least 12 weeks

- Histologic documentation of adenocarcinoma of the prostate

- Surgical castration or ongoing use of gonadotropin-releasing hormone agonists with
confirmed castrate levels of testosterone

- Metastatic progressive CRPC defined as progressive disease despite surgical
castration or ongoing use of gonadotropin-releasing hormone agonists with confirmed
castrate levels of testosterone

- For patients in the dose-expansion cohort of the study, not more than two prior lines
of cytotoxic chemotherapy in the metastatic setting

- Evaluable or measurable disease

- Documented willingness to use an effective means of contraception

Exclusion Criteria:

- Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal
therapy, or radiotherapy within 4 weeks prior to Day 1, with the following
exceptions: maintenance hormonal therapy for metastatic prostate cancer and
palliative radiation to bone metastases within 2 weeks prior to Day 1

- Major surgical procedure within 4 weeks prior to Day 1

- Known active bacterial, viral, fungal, mycobacterial, or other infection (including
HIV and atypical mycobacterial disease, but excluding fungal infections of the nail
beds)

- Ongoing corticosteroid use with > 10 mg of daily prednisone or equivalent

- Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy. Patients
who are receiving bisphosphonate therapy specifically to prevent skeletal events and
who do not have a history of clinically significant hypercalcemia are eligible.

- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
(or recombinant antibody-related fusion proteins)

- Clinically significant history of liver disease, including viral or other hepatitis,
current alcohol abuse, or cirrhosis

- Untreated or active central nervous system (CNS) metastases. Patients with a history
of treated CNS metastases are eligible, provided that they meet all of the following
criteria: evaluable or measurable disease outside the CNS, radiographic demonstration
of improvement upon the completion of CNS-directed therapy and no evidence of interim
progression between the completion of CNS-directed therapy and the screening
radiographic study, and screening CNS radiographic study is >/= 8 weeks since
completion of radiotherapy and >/= 4 weeks since the discontinuation of
corticosteroids and anticonvulsants

- Dose expansion cohort (B): no prior chemotherapy is allowed
We found this trial at
5
sites
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials